Eplontersen (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code

Report documents

1. Extract of dossier assessment

   Eplontersen (hereditäre Transthyretin-Amyloidose mit Polyneuropathie) – Nutzenbewertung gemäß § 35a SGB V

   published on

   01.08.2025

   Document type

   PDF document, 244 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-52_en

   Download file : Extract of dossier assessment (PDF document, 244 kB, EN, not accessible)
2. Dossier assessment

   Eplontersen (hereditäre Transthyretin-Amyloidose mit Polyneuropathie) – Nutzenbewertung gemäß § 35a SGB V

   published on

   01.08.2025

   Document type

   PDF document, 525 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/A25-52

   Download file : Dossier assessment (PDF document, 525 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A25-52

Commission

Commission awarded on 28.04.2025 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Digestion, metabolism and hormones

Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-52